Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Nov 14;11(11):CD005449.
doi: 10.1002/14651858.CD005449.pub2.

Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus

Nyoli Valentine  1 , Floris A Van de Laar, Mieke L van Driel
Affiliations
Meta-Analysis

Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus

Nyoli Valentine et al. Cochrane Database Syst Rev. .

Abstract

Background: Cardiovascular disease (CVD) is the most prevalent complication of type 2 diabetes with an estimated 65% of people with type 2 diabetes dying from a cause related to atherosclerosis. Adenosine-diphosphate (ADP) receptor antagonists like clopidogrel, ticlopidine, prasugrel and ticagrelor impair platelet aggregation and fibrinogen-mediated platelet cross-linking and may be effective in preventing CVD.

Objectives: To assess the effects of adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (issue 2, 2011), MEDLINE (until April 2011) and EMBASE (until May 2011). We also performed a manual search, checking references of original articles and pertinent reviews to identify additional studies.

Selection criteria: Randomised controlled trials comparing an ADP receptor antagonist with another antiplatelet agent or placebo for a minimum of 12 months in patients with diabetes. In particular, we looked for trials assessing clinical cardiovascular outcomes.

Data collection and analysis: Two review authors extracted data for studies which fulfilled the inclusion criteria, using standard data extraction templates. We sought additional unpublished information and data from the principal investigators of all included studies.

Main results: Eight studies with a total of 21,379 patients with diabetes were included. Three included studies investigated ticlopidine compared to aspirin or placebo. Five included studies investigated clopidogrel compared to aspirin or a combination of aspirin and dipyridamole, or compared clopidogrel in combination with aspirin to aspirin alone. All trials included patients with previous CVD except the CHARISMA trial which included patients with multiple risk factors for coronary artery disease. Overall the risk of bias of the trials was low. The mean duration of follow-up ranged from 365 days to 913 days.Data for diabetes patients on all-cause mortality, vascular mortality and myocardial infarction were only available for one trial (355 patients). This trial compared ticlopidine to placebo and did not demonstrate any statistically significant differences for all-cause mortality, vascular mortality or myocardial infarction. Diabetes outcome data for stroke were available in three trials (31% of total diabetes participants). Overall pooling of two (statistically heterogeneous) studies showed no statistically significant reduction in the combination of fatal and non-fatal stroke (359/3194 (11.2%) versus 356/3146 (11.3%), random effects odds ratio (OR) 0.81; 95% confidence interval (CI) 0.44 to 1.49) for ADP receptor antagonists versus other antiplatelet drugs. There were no data available from any of the trials on peripheral vascular disease, health-related quality of life, adverse events specifically for patients with diabetes, or costs.

Authors' conclusions: The available evidence for ADP receptor antagonists in patients with diabetes mellitus is limited and most trials do not report outcomes for patients with diabetes separately. Therefore, recommendations for the use of ADP receptor antagonists for the prevention of CVD in patients with diabetes are based on available evidence from trials including patients with and without diabetes. Trials with diabetes patients and subgroup analyses of patients with diabetes in trials with combined populations are needed to provide a more robust evidence base to guide clinical management in patients with diabetes.

PubMed Disclaimer

Conflict of interest statement

No declarations are known for Nyoli Valentine, Floris van de Laar or Mieke van Driel.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 All‐cause mortality, Outcome 1 Ticlopidine vs placebo.
2.1
2.1. Analysis
Comparison 2 Vascular mortality, Outcome 1 Ticlopidine vs placebo.
3.1
3.1. Analysis
Comparison 3 Stroke (fatal and non‐fatal), Outcome 1 Ticlodipine vs placebo.
3.2
3.2. Analysis
Comparison 3 Stroke (fatal and non‐fatal), Outcome 2 Ticlodipine vs aspirin.
3.3
3.3. Analysis
Comparison 3 Stroke (fatal and non‐fatal), Outcome 3 Clopidogrel vs aspirin & dipyridamole.
3.4
3.4. Analysis
Comparison 3 Stroke (fatal and non‐fatal), Outcome 4 ADP receptor antagonists vs other antiplatelet drug.
4.1
4.1. Analysis
Comparison 4 Myocardial infarction (fatal and non‐ fatal), Outcome 1 Ticlopidine/Placebo.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD005449

References

References to studies included in this review

AAASPS 2003 {published data only (unpublished sought but not used)}
    1. Gorelick PB, Leurgans S, Richardson J, Harris Y, Billingsley M and the AAASPS Investigators. African American Antiplatelet Stroke Prevention Study: clinical trial design. Journal of Stroke and Cerebrovascular Diseases 1998;7(6):426‐34. - PubMed
    1. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients. JAMA 2003;289(22):2947‐57. - PubMed
CAPRIE 1996 {published data only (unpublished sought but not used)}
    1. Bhatt DL, Marso SP, Hirsch AT, Tingleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. The American Journal of Cardiology 2002;90:625‐8. - PubMed
    1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet 1996;348(9038):1329‐39. - PubMed
    1. Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vascular Medicine 1998;3(3):257‐60. - PubMed
    1. Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Safety 1999;21(4):325‐35. - PubMed
    1. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high‐risk patient populations. Archives of Internal Medicine 2004;164:2106‐10. - PubMed
CATS 1988 {published and unpublished data}
    1. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organisation, and baseline results. Stroke 1988;19:1203‐10. - PubMed
    1. Gent M, Easton JD, Hachinski VC, Panak E, Sicurella J, Blakely JA, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. The Lancet 1989;8649:1215‐20. - PubMed
    1. Gent M, Ellis D. Canadian American ticlopidine study (cats) in thromboembolic stroke. Agents and Actions. Supplements 1984;15:283‐96. - PubMed
CHARISMA 2002 {published data only (unpublished sought but not used)}
    1. Bakhru MR, Bhatt DL. Interpreting the CHARISMA study. What is the role of dual antiplatelet therapy with clopidogrel and aspirin?. Cleveland Clinic Journal of Medicine 2008;75(4):289‐95. - PubMed
    1. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology 2007;49(19):1982‐8. - PubMed
    1. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The New England Journal of Medicine 2006;354(16):1706‐17. - PubMed
    1. Bhatt DL, Topol EJ, on behalf of the CHARISMA Executive Committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high‐risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal 2004;148( 2 ):263‐8. - PubMed
    1. Collet JP, Montalescot G, Steg PG, Steinhubl SR, Fox KA, Hu TF, et al. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Archives of Cardiovascular Diseases 2009;102(6‐7):485‐96. - PubMed
CURE 1998 {published data only (unpublished sought but not used)}
    1. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non‐ST‐elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110(10):1202‐8. - PubMed
    1. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high‐risk patient populations: Lessons from the CAPRIE and CURE studies. Archives of Internal Medicine 2004;164(19):2106‐10. - PubMed
    1. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study . Circulation 2003;108(12):1682‐7. - PubMed
    1. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation. The New England Journal of Medicine 2001;345(7):494‐502. - PubMed
Park 2010 {published data only (unpublished sought but not used)}
    1. Park SJ, Park DW, Kim YH. Duration of dual antiplatelet therapy after implantation of drug‐eluding stents. The New England Journal of Medicine 2010;362(15):1374‐82. - PubMed
PRoFESS 2008 {published data only (unpublished sought but not used)}
    1. Bath PM, Cotton D, Martin RH, Palesch Y, Yusuf S, Sacco R, et al. Effect of combined aspirin and extended‐release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke 2010;41(4):732‐8. - PubMed
    1. Diener HC. The PRoFESS trial: future impact on secondary stroke prevention. Expert Review of Neurotherapeutics 2007;7(9):1085‐91. - PubMed
    1. Diener HS, Sacco R, Yusuf S, for the Steering Committee and PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases 2007;23(5‐6):368‐80. - PubMed
    1. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, for the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. The New England Journal of Medicine 2008;359(12):1238‐51. - PMC - PubMed
TASS 1989 {published data only (unpublished sought but not used)}
    1. Bellavance A. Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The ticlopidine aspirin stroke study. Stroke 1993;24(10):1452‐7. - PubMed
    1. Grutta JC, Norris JW, Kamin B and the TASS Baseline and Angiographic Data Subgroup. Prevention of stroke with ticlopidine: Who benefits most?. Neurology 1992;42( 1 ):111‐5. - PubMed
    1. Harbison JW. Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the ticlopidine aspirin stroke study. Stroke 1992;23(12):1723‐7. - PubMed
    1. Hass WK, Easton J, Adams HP, Pryse‐Phillips W, Molony BA, for the Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high‐risk patients. The New England Journal of Medicine 1989;321(8):501‐7. - PubMed
    1. Pryse‐Phillips WAU, for the TASS Group. Ticlopidine aspirin stroke study: outcome by vascular distribution of the qualifying event. Journal of Stroke and Cerebrovascular Diseases 1993;3:49‐56. - PubMed

References to studies excluded from this review

Balsano 1990 {published data only}
    1. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation 1990;82(1):17‐26. - PubMed
CHANCE 2010 {published data only}
    1. Wang Y, Johnston SC, for the CHANCE investigators. Rationale and design of a randomized, double‐blind trial comparing the effects of a 3‐month clopidogrel‐aspirin regimen versus aspirin alone for the treatment of high‐risk patients with acute nondisabling cerebrovascular event. American Heart Journal 2010;160(3):380‐6. - PubMed
CLARITY 2005 {published data only}
    1. Sabatine MS, Cannon CP, Gibson CM, López‐Sendón JL, Montalescot G, Theroux P, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST‐elevation myocardial infarction treated with fibrinolytics: the PCI‐CLARITY study. JAMA 2005;294(10):1224‐32. - PubMed
COMMIT 2005 {published data only}
    1. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. The Lancet 2005;366(9497):1607‐21. - PubMed
CREDO 2002 {published data only}
    1. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19):2411‐20. - PubMed
Cun 2002 {published data only}
    1. Cun VG, Temuzhan A, Pekdemur H, Toka M, Tartanoglu O. The effects of ticlopidine in acute myocardial infarction as an adjunctive treatment to aspirin in an intermediate term setting. Turkish Journal of Medical Sciences 2002;32(4):329‐34.
Harrington 2009 {published data only}
    1. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, et al. Platelet inhibition with cangrelor in patients undergoing PCI. The New England Journal of Medicine 2009;361(24):2318‐29. - PubMed
Ishikawa 1997 {published data only}
    1. Ishikawa K, Kanamasa K, Hama J, Ogawa I, Takenaka T, Naito T, et al. Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. Japanese Circulation Journal 1997;61(1):38‐45. - PubMed
JUMBO TIMI 2005 {published data only}
    1. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, et al. Randomized comparison of prasugrel (CS‐747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)‐TIMI 26 trial. Circulation 2005;111(25):3366‐73. - PubMed
Li 1999 {published data only}
    1. Li YZ, Wang L, Yu PX. A randomized trial comparing ticlopidine with aspirin for the prevention of ischaemic cerebral stroke. Acta Pharmacologica Sinica 1999;20(5):476.
Machraoui 2001 {published data only}
    1. Machraoui A, Germing A, Lindstaedt M, Dryander S, Bojara W, Lawo T, et al. Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting: follow‐up results of a randomized study. Journal of Invasive Cardiology June 2001;13(6):431‐6. - PubMed
MATCH 2004 {published data only}
    1. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high‐risk patients (MATCH): randomised, double‐blind, placebo‐controlled trial. The Lancet 2004;364(9431):331‐7. - PubMed
Mueller 2003 {published data only}
    1. Mueller C, Roskamm H, Neumann FJ, Hunziker P, Marsch S, Perruchoud A, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. Journal of the American College of Cardiology 2003;41(6):969‐73. - PubMed
PLATO 2006 {published data only}
    1. Wallentin L, Becker RC, Budaj A, Cannon C, for the PLATO investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine 2009;361(11):1045‐57. - PubMed
STAMI 2001 {published data only}
    1. Scrutinio D, Cimminiello C, Marubini E, Pitzalis MV, Biase M, Rizzon P. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. Journal of American College of Cardiology 2001;37(5):1259‐65. - PubMed
STIMS 1990 {published data only}
    1. Janzon L, Berggvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. Journal of Internal Medicine 1990;227(5):301‐8. - PubMed
TISS 1997 {published data only}
    1. Bergamasco B, Benna P, Carolei A, Rasura M, Rudelli G, Fieschi C. A randomized trial comparing ticlopidine hydrochloride with ibuprofen for the prevention of stroke in high‐risk patients (TISS Study). Ticlopidine Indobufen Stroke Study. Functional Neurology 1997;12(1):33‐43. - PubMed
Tohgi 1987 {published data only}
    1. Tohgi H, Murakami M. The effect of ticlopidine on TIA compared with aspirin ‐ a double‐blind, twelve‐month and open 24 month follow up study. Japanese Journal of Medicine 1987;26(1):117‐9.
TOPALS 2003 {published data only}
    1. Ito E, Takahashi A, Yamamoto H, Kuzuhara S, Uchiyama S, Nakajima M. Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke (the Tokai Panaldine Aspirin Long‐term Study (TOPALS)). Internal Medicine 2003;42(9):793‐9. - PubMed
TRITON‐TIMI 38 2008 {published data only}
    1. Wivott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine 2007;357(20):2001‐15. - PubMed

References to ongoing studies

SPS3 2011 {published data only}
    1. Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente MF, and the SPS3 Investigators. The secondary prevention of small subcortical strokes (SPS3) study. International Journal of Stroke April 2011;6(2):164‐75. - PMC - PubMed

Additional references

ADA 1997
    1. American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20(7):1183‐97. - PubMed
ADA 1999
    1. American Diabetes Association. The Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22(Suppl 1):S1‐114. - PubMed
ADA 2011
    1. American Diabetes Association. Standards of medical care in diabetes‐2011. Diabetes Care 2011;34(Suppl 1):s11‐61. - PMC - PubMed
Angiolillo 2009
    1. Angiolillo DJ, Suryadevara S. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Practice & Research Clinical Endocrinology & Metabolism 2009 Jun;23(3):375‐88. - PubMed
Antithrombotic Trialists' Collaboration 2002
    1. Antithrombotic Trialists' Collaboration. Collaborative meta‐analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71‐86. - PMC - PubMed
Bhatt 2002
    1. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. American Journal of Cardiology 2002;90(6):625‐8. [MEDLINE: ] - PubMed
Ceriello 2004
    1. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arteriosclerosis, thrombosis, and vascular biology 1: Arteriosclerosis, thrombosis, and vascular biology 2004;24(5):816‐23. [MEDLINE: ] - PubMed
Colwell 2003
    1. Colwell JA. Aspirin for primary prevention of cardiovascular events in diabetes. Diabetes Care 2003;26(12):3349‐50. [MEDLINE: ] - PubMed
Goodwin 2011
    1. Goodwin MM, Desilets AR, Willett KC. Thienopyridines in acute coronary syndrome. The Annals of Pharmacotherapy 2011;45(2):207‐17. - PubMed
Gu 1998
    1. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971‐1993. Diabetes Care 1998;21(7):1138‐45. [MEDLINE: ] - PubMed
Haffner 1998
    1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine 1998;339(4):229‐34. [MEDLINE: ] - PubMed
Higgins 2002
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analysis. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Kam 2003
    1. Kam, CA, Nethery, CM. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and developments. Anaesthesia 2003;58(1):28‐35. - PubMed
Kutti 1986
    1. Kutti J, Wadenvik H, Henestam B, Stenstrom G. Evaluation of platelet reactivity in diabetes mellitus. Acta Medica Scandinavica 1986;219(2):195‐9. [MEDLINE: ] - PubMed
Lau 2006
    1. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597‐600. - PMC - PubMed
Liberati 2009
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic and meta‐analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine 1999;6(7):1‐28. [DOI: 10.1371/journal.pmed.1000100] - DOI - PMC - PubMed
NICE 2010
    1. National Insitute for Health and Clinical Excellence. Unstable angina and NSTEMI. The early management of unstable angina and non‐ST‐segment‐elevation myocardial infarction. Clinical guideline 94. http://guidance.nice.org.uk/CG94/NICEGuidance/pdf/English (accessed March 2010).
Squizzato 2011
    1. Squizzato A, Keller T, Romualdi E, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD005158.pub3] - DOI - PubMed
Sterne 2001
    1. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care; Meta‐analysis in Context. London: BMJ Publishing Group, 2001:189‐208.
Sudlow 2009
    1. Sudlow CLM, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD001246.pub2] - DOI - PMC - PubMed
WHO 1980
    1. WHO Expert Committee on Diabetes Mellitus. Second report. World Health Organisation: Technical Report Series 646; 1980. - PubMed
WHO 1985
    1. World Health Organisation. Diabetes Mellitus: Report of a WHO Study Group. World Health Organisation: Technical Report Series No. 727; 1985. - PubMed
WHO 1998
    1. Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15(7):539‐53. - PubMed
Wild 2004
    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047‐53. [MEDLINE: ] - PubMed

Publication types

MeSH terms

LinkOut - more resources